Drugs / Recombinant Human Thymosin β4
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04555850 | Jul 2018 → Feb 2019 | — | Beijing Northland Biotech. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04555824 | Jul 2017 → Feb 2018 | — | Beijing Northland Biotech. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Thymosin β4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04555850 ↗ |
| Known as | NL005 | “The objective of this study is to evaluate the safety, tolerance, pharmacokinetics and the potential immunological reaction of single intravenous recombinant human thymosin...” NCT04555850 ↗ |
| Modality | Protein / enzyme biologic | “single intravenous recombinant human thymosin β4” NCT04555824 ↗ |
| Route | Intravenous | “single intravenous dose of rh-Tβ4 in Day1” NCT04555824 ↗ |